+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drugs for PrEP Market - Global Forecast 2026-2032- Product Image
Drugs for PrEP Market - Global Forecast 2026-2032- Product Image
Sale

Drugs for PrEP Market - Global Forecast 2026-2032

  • Report

  • 180 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6117982
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Drugs for PrEP Market is projected to reach USD 2.51 Billion in 2026. It is expected to continue growing at a CAGR of 8.26%, reaching USD 4.08 Billion by 2032.

Drugs for PrEP: Executive Summary and Market Context

Pre-exposure prophylaxis (PrEP) comprises antiretroviral medicines used by people who do not have HIV to reduce the risk of acquiring it. The field includes oral and long-acting options, with product selection shaped by clinical eligibility, adherence, access, affordability, prescribing capacity, and local HIV epidemiology. This executive summary focuses on evidence-based developments affecting prevention delivery without presenting market estimates, market shares, forecasts, or company-specific analysis.

Prevention Is Shifting Toward Choice, Long-Acting Delivery, and Integrated Care

The PrEP landscape is moving from reliance on daily oral tablets toward differentiated prevention choices, including event-driven approaches where clinically appropriate and long-acting injectable regimens in settings where they are authorized and accessible. This shift increases the importance of screening, renal and hepatitis B assessment, injection scheduling, follow-up testing, pharmacovigilance, and clear counseling about HIV status and sexually transmitted infections. Persistent barriers include stigma, uneven provider knowledge, supply continuity, regulatory variation, and the need to reach populations that experience limited access to conventional health services.

Artificial Intelligence Can Improve PrEP Delivery, but Clinical Governance Is Essential

Artificial intelligence can support PrEP programs by identifying missed appointments, helping prioritize outreach, improving demand and inventory planning, translating educational materials, and assisting clinicians with guideline-based documentation. Its value depends on representative data, privacy protection, explainability, cybersecurity, and human oversight. Algorithms must not reinforce unequal access or infer sensitive sexual-health information without appropriate consent. AI should complement-not replace-clinical testing, adherence counseling, shared decision-making, and public-health accountability.

Regional Insights: Access and Delivery Models Differ Across Six Major Geographies

North America has comparatively established PrEP awareness and clinical infrastructure, but coverage gaps remain among uninsured, rural, marginalized, and stigmatized populations. Latin America is advancing prevention services while facing differences in regulatory approval, procurement, financing, and provider capacity. Europe combines strong public-health systems with varied national guidelines, reimbursement arrangements, and uptake across countries. The Middle East requires context-sensitive approaches that address confidentiality, stigma, and uneven service availability. Africa remains central to global prevention efforts, with major opportunities to expand community delivery, testing integration, and differentiated care. Asia-Pacific presents substantial diversity: some systems have mature prevention programs, while others need stronger awareness, domestic financing, and implementation capacity.

Group Insights: Regional Blocs Influence Procurement, Standards, and Implementation

ASEAN countries differ widely in HIV burden, health-system capacity, regulatory pathways, and community-led prevention infrastructure, making adaptable regional cooperation valuable. BRICS members span large and diverse populations and can strengthen prevention through domestic manufacturing, public procurement, research collaboration, and differentiated service delivery, while national approaches remain distinct. The European Union benefits from cross-border scientific and public-health collaboration, although reimbursement and implementation decisions are primarily national. G7 members can contribute evidence, financing, and technical support while addressing inequities within their own populations. GCC countries may leverage centralized health systems and testing capacity, with confidentiality and culturally appropriate services remaining important. NATO is not a health-policy bloc, but its members can share preparedness, supply-chain, and service-continuity practices relevant to prevention resilience.

Country Insights: National Priorities Range from Scale-Up to Equity and Integration

Australia has experience with community-informed prevention and can continue integrating PrEP into primary and sexual-health services. Brazil combines national public-health capacity with the need to sustain equitable access across regions. Canada must address geographic, Indigenous, and socioeconomic disparities alongside provincial and territorial variation. China’s priorities include awareness, testing linkage, and access across diverse populations. France, Germany, Italy, and Spain each require alignment among national guidance, reimbursement, clinical capacity, and stigma reduction. India’s scale makes differentiated delivery, affordability, and community engagement especially important. Japan and South Korea can benefit from stronger awareness, routine risk assessment, and confidential access pathways. Mexico faces regional and health-system variation that makes decentralized delivery valuable. Russia’s prevention environment is shaped by regulatory, epidemiological, and service-access conditions. The United Kingdom and United States have substantial clinical experience but continue to confront disparities, retention challenges, and uneven access between communities.

Action Priorities for Leaders: Build Choice, Trust, and Continuity into PrEP Programs

Industry leaders should expand person-centered choice across appropriate oral and long-acting options; pair every regimen with reliable HIV testing, follow-up, and prevention counseling; and design services with affected communities rather than for them. They should strengthen procurement and cold-chain or appointment systems where relevant, train primary-care and community providers, simplify eligibility and refill pathways, and use transparent affordability and access policies. Leaders should establish measurable equity objectives, monitor initiation and persistence without compromising privacy, and apply AI only within validated governance frameworks. Partnerships with public-health agencies, community organizations, laboratories, and pharmacies can improve reach while preserving clinical responsibility.

Research Methodology: Evidence-Led Synthesis of PrEP Policy and Delivery Factors

This executive summary uses a structured qualitative synthesis of established clinical, public-health, regulatory, and implementation considerations for HIV PrEP. The analysis organizes findings across treatment innovation, service delivery, digital tools, regions, multilateral groups, and specified countries. It emphasizes verifiable themes such as regimen differentiation, testing requirements, adherence, stigma, health-system capacity, equity, and governance. No market estimates, market sizing, market shares, forecasts, or company-specific claims are included. Country and group observations are intentionally high-level and should be validated against current national guidelines, regulatory status, reimbursement rules, and epidemiological surveillance before operational decisions are made.

Conclusion: Sustainable PrEP Impact Depends on Equitable, Integrated Prevention Systems

PrEP is most effective as part of a trusted prevention system that offers clinically appropriate choice, dependable testing, respectful counseling, and continuity of access. Long-acting delivery and carefully governed digital tools can help overcome adherence and service barriers, but they do not substitute for community engagement or strong health infrastructure. Across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific-and within the identified country and group contexts-leaders should prioritize equity, confidentiality, evidence-based implementation, and resilient supply and care pathways.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Drugs for PrEP Market, by Product Type
7.1. Introduction
7.2. Branded
7.2.1. Apretude
7.2.2. Descovy
7.2.3. Truvada
7.3. Generic
8. Drugs for PrEP Market, by Administration Route
8.1. Introduction
8.2. Injectable
8.3. Oral
9. Drugs for PrEP Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
9.4.1. Chain Pharmacy
9.4.2. Independent Pharmacy
10. Drugs for PrEP Market, by Mechanism Of Action
10.1. Introduction
10.2. Integrase Strand Transfer Inhibitors
10.3. Nucleotide Reverse Transcriptase Inhibitors
11. Drugs for PrEP Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Drugs for PrEP Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Drugs for PrEP Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. AbbVie Inc.
15.2. Astellas Pharma Inc.
15.3. Aurobindo Pharma Limited
15.4. Boehringer Ingelheim International GmbH
15.5. Bristol Myers Squibb Company
15.6. Cipla Limited
15.7. Emcure Pharmaceuticals Limited
15.8. Gilead Sciences, Inc.
15.9. GlaxoSmithKline plc
15.10. Hetero Labs Limited
15.11. Janssen Pharmaceuticals, Inc.
15.12. Lupin Limited
15.13. Macleods Pharmaceuticals Ltd.
15.14. Merck KGaA
15.15. Mylan N.V.
15.16. Novartis AG
15.17. Pfizer Inc.
15.18. Sanofi SA
15.19. Sun Pharmaceutical Industries Ltd.
15.20. Teva Pharmaceutical Industries Ltd.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Drugs for PrEP Market, Years Considered for the Study
FIGURE 2. Global Drugs for PrEP Market, Research Design
FIGURE 3. Global Drugs for PrEP Market, Research Framework
FIGURE 4. Global Drugs for PrEP Market, Data Triangulation
FIGURE 5. Global Drugs for PrEP Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Drugs for PrEP Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Drugs for PrEP Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Drugs for PrEP Market Size, by Administration Route, 2025 vs 2032 (%)
FIGURE 9. Global Drugs for PrEP Market Size, by Administration Route, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Drugs for PrEP Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 11. Global Drugs for PrEP Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Drugs for PrEP Market Size, by Mechanism Of Action, 2025 vs 2032 (%)
FIGURE 13. Global Drugs for PrEP Market Size, by Mechanism Of Action, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Drugs for PrEP Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Drugs for PrEP Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Drugs for PrEP Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Drugs for PrEP Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Drugs for PrEP Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Drugs for PrEP Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Drugs for PrEP Market Segmentation & Coverage
TABLE 2. Global Drugs for PrEP Market Size, 2017-2032 (USD Million)
TABLE 3. Global Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Branded Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Branded Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Branded Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Apretude Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Apretude Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Apretude Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Descovy Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Descovy Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Descovy Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Truvada Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Truvada Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Truvada Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Generic Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Generic Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Generic Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 20. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 27. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Chain Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Chain Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Chain Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Independent Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Independent Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Independent Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 43. Global Integrase Strand Transfer Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Integrase Strand Transfer Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Integrase Strand Transfer Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Nucleotide Reverse Transcriptase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Nucleotide Reverse Transcriptase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Nucleotide Reverse Transcriptase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Drugs for PrEP Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Asia-Pacific Drugs for PrEP Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Asia-Pacific Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 52. Asia-Pacific Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 53. Asia-Pacific Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 54. Asia-Pacific Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 55. Asia-Pacific Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 56. Asia-Pacific Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 57. North America Drugs for PrEP Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. North America Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 59. North America Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 60. North America Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 61. North America Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 62. North America Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 63. North America Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 64. Latin America Drugs for PrEP Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Latin America Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 66. Latin America Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 67. Latin America Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 68. Latin America Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 69. Latin America Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 70. Latin America Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 71. Europe Drugs for PrEP Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Europe Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 73. Europe Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 74. Europe Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 75. Europe Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 76. Europe Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 77. Europe Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 78. Middle East Drugs for PrEP Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Middle East Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 80. Middle East Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 81. Middle East Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 82. Middle East Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 83. Middle East Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 84. Middle East Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 85. Africa Drugs for PrEP Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Africa Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 87. Africa Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 88. Africa Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 89. Africa Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 90. Africa Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 91. Africa Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 92. Global Drugs for PrEP Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. ASEAN Drugs for PrEP Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. ASEAN Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 95. ASEAN Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 96. ASEAN Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 97. ASEAN Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 98. ASEAN Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 99. ASEAN Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 100. GCC Drugs for PrEP Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. GCC Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 102. GCC Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 103. GCC Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 104. GCC Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 105. GCC Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 106. GCC Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 107. European Union Drugs for PrEP Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. European Union Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 109. European Union Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 110. European Union Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 111. European Union Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 112. European Union Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 113. European Union Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 114. BRICS Drugs for PrEP Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. BRICS Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 116. BRICS Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 117. BRICS Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 118. BRICS Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 119. BRICS Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 120. BRICS Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 121. G7 Drugs for PrEP Market Size, by Group, 2017-2032 (USD Million)
TABLE 122. G7 Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 123. G7 Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 124. G7 Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 125. G7 Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 126. G7 Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 127. G7 Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 128. NATO Drugs for PrEP Market Size, by Group, 2017-2032 (USD Million)
TABLE 129. NATO Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 130. NATO Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 131. NATO Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 132. NATO Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 133. NATO Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 134. NATO Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 135. Global Drugs for PrEP Market Size, by Country, 2017-2032 (USD Million)
TABLE 136. United States Drugs for PrEP Market Size, 2017-2032 (USD Million)
TABLE 137. United States Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 138. United States Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 139. United States Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 140. United States Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 141. United States Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 142. United States Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 143. Canada Drugs for PrEP Market Size, 2017-2032 (USD Million)
TABLE 144. Canada Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 145. Canada Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 146. Canada Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 147. Canada Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 148. Canada Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 149. Canada Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 150. Mexico Drugs for PrEP Market Size, 2017-2032 (USD Million)
TABLE 151. Mexico Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 152. Mexico Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 153. Mexico Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 154. Mexico Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 155. Mexico Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 156. Mexico Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 157. Brazil Drugs for PrEP Market Size, 2017-2032 (USD Million)
TABLE 158. Brazil Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 159. Brazil Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 160. Brazil Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 161. Brazil Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 162. Brazil Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 163. Brazil Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 164. United Kingdom Drugs for PrEP Market Size, 2017-2032 (USD Million)
TABLE 165. United Kingdom Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 166. United Kingdom Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 167. United Kingdom Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 168. United Kingdom Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 169. United Kingdom Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 170. United Kingdom Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 171. Germany Drugs for PrEP Market Size, 2017-2032 (USD Million)
TABLE 172. Germany Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 173. Germany Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 174. Germany Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 175. Germany Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 176. Germany Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 177. Germany Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 178. France Drugs for PrEP Market Size, 2017-2032 (USD Million)
TABLE 179. France Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 180. France Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 181. France Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 182. France Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 183. France Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 184. France Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 185. Russia Drugs for PrEP Market Size, 2017-2032 (USD Million)
TABLE 186. Russia Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 187. Russia Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 188. Russia Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 189. Russia Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 190. Russia Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 191. Russia Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 192. Italy Drugs for PrEP Market Size, 2017-2032 (USD Million)
TABLE 193. Italy Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 194. Italy Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 195. Italy Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 196. Italy Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 197. Italy Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 198. Italy Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 199. Spain Drugs for PrEP Market Size, 2017-2032 (USD Million)
TABLE 200. Spain Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 201. Spain Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 202. Spain Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 203. Spain Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 204. Spain Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 205. Spain Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 206. China Drugs for PrEP Market Size, 2017-2032 (USD Million)
TABLE 207. China Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 208. China Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 209. China Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 210. China Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 211. China Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 212. China Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 213. India Drugs for PrEP Market Size, 2017-2032 (USD Million)
TABLE 214. India Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 215. India Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 216. India Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 217. India Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 218. India Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 219. India Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 220. Japan Drugs for PrEP Market Size, 2017-2032 (USD Million)
TABLE 221. Japan Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 222. Japan Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 223. Japan Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 224. Japan Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 225. Japan Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 226. Japan Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 227. Australia Drugs for PrEP Market Size, 2017-2032 (USD Million)
TABLE 228. Australia Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 229. Australia Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 230. Australia Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 231. Australia Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 232. Australia Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 233. Australia Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 234. South Korea Drugs for PrEP Market Size, 2017-2032 (USD Million)
TABLE 235. South Korea Drugs for PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 236. South Korea Drugs for PrEP Market Size, by Branded, 2017-2032 (USD Million)
TABLE 237. South Korea Drugs for PrEP Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 238. South Korea Drugs for PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 239. South Korea Drugs for PrEP Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 240. South Korea Drugs for PrEP Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 241. Global Drugs for PrEP Market Share, by Key Player, 2025
TABLE 242. Global Drugs for PrEP Market, Key Experts

Companies Mentioned

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Emcure Pharmaceuticals Limited
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Labs Limited
  • Janssen Pharmaceuticals, Inc.
  • Lupin Limited
  • Macleods Pharmaceuticals Ltd.
  • Merck KGaA
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Related Topics

Related Reports

Parenteral PrEP Market - Global Forecast 2026-2032 - Product Image

Parenteral PrEP Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Rabavert Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Rabavert Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 250 Pages
  • Global
From
Regen-cov and Ronapreve Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Regen-cov and Ronapreve Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 250 Pages
  • Global
From
Pharmaceutical Sample Preprocessing System Market - Global Forecast 2026-2032 - Product Image

Pharmaceutical Sample Preprocessing System Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Counterfeit Drug Detection Device - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Counterfeit Drug Detection Device - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 125 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.